Amorphous Solid Dispersion (ASD) technology has emerged as a promising strategy to enhance the solubility and bioavailability of poorly water-soluble drugs, such as Paclitaxel, a key agent in cancer therapy. Despite its significant antitumor activity against various malignancies, Paclitaxel's clinical application has been hampered by its low solubility and adverse effects associated with its conventional formulation, which utilizes Cremophor® EL. This review highlights recent advancements in ASD formulations aimed at improving Paclitaxel delivery through innovative polymer systems, nanotechnology, and advanced manufacturing techniques such as spray drying and hot melt extrusion..........

Keywords : Amorphous Solid Dispersion (ASD), Paclitaxel, Solubility, Bioavailability, Polymer, Drug delivery, Passive diffusion, Cancer therapy.

[1]. Paclitaxel ASD formulation in Nanotechnology (https://www.sciencedirect.com/science/article/abs/pii/S093964111930479X)
[2]. Amorphous Solid Dispersion of Paclitaxel (https://link.springer.com/article/10.1007/s11095-010-0174-2)
[3]. Recent Advances in ASD for Chemotherapy Drugs (https://www.mdpi.com/1999-4923/13/2/168)
[4]. Baghel, S.; Cathcart, H.; O'Reilly, N.J. Polymeric Amorphous Solid Dispersions: A Review of Amorphization, Crystallization, Stabilization, Solid-State Characterization, and Aqueous Solubilization of Biopharmaceutical Classification System Class II Drugs. J. Pharm. Sci. 2016, 105, 2527–2544. [Google Scholar] [CrossRef] [PubMed] [Green Version]

[5]. Vo, C.L.-N.; Park, C.; Lee, B.-J. Current Trends and Future Perspectives of Solid Dispersions Containing Poorly Water-Soluble Drugs. Eur. J. Pharm. Biopharm. 2013, 85, 799–813. [Google Scholar] [CrossRef] [PubMed]